ADMA Biologics Inc EBIT Margin 2013-2024 | ADMA

ADMA Biologics Inc ebit margin for the quarter ending June 30, 2024 was 25.45%.

  • ADMA Biologics Inc average ebit margin for 2023 was -3.01%, a 92.87% decline from 2022.
  • ADMA Biologics Inc average ebit margin for 2022 was -42.19%, a 57.77% decline from 2021.
  • ADMA Biologics Inc average ebit margin for 2021 was -99.9%, a 28.34% decline from 2020.

Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues

ADMA Biologics Inc EBIT Margin 2013-2024 | ADMA

  • ADMA Biologics Inc average ebit margin for 2023 was -3.01%, a 92.87% decline from 2022.
  • ADMA Biologics Inc average ebit margin for 2022 was -42.19%, a 57.77% decline from 2021.
  • ADMA Biologics Inc average ebit margin for 2021 was -99.9%, a 28.34% decline from 2020.

Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$160.6B
Vertex Pharmaceuticals (VRTX)$126.2B
Bristol Myers Squibb (BMY)$119.7B
Gilead Sciences (GILD)$117.5B
Regeneron Pharmaceuticals (REGN)$90.2B
CSL (CSLLY)$90B
GSK (GSK)$73.6B
Argenex SE (ARGX)$35.5B
Alnylam Pharmaceuticals (ALNY)$34.7B
BioNTech SE (BNTX)$25.5B
Biogen (BIIB)$24.5B
Illumina (ILMN)$23.4B
BeiGene (BGNE)$18.9B
Moderna (MRNA)$16.7B
Incyte (INCY)$15.5B
Genmab (GMAB)$14.9B
BioMarin Pharmaceutical (BMRN)$12.6B
Insmed (INSM)$12.5B
Vaxcyte (PCVX)$12.4B
Bio-Techne Corp (TECH)$11.8B
Sarepta Therapeutics (SRPT)$10.9B
Exelixis (EXEL)$10.2B
Revolution Medicines (RVMD)$10B
QIAGEN (QGEN)$9.9B
Intra-Cellular Therapies (ITCI)$9.4B
Bio-Rad Laboratories (BIO.B)$9.4B
Exact Sciences (EXAS)$9.3B
Roivant Sciences (ROIV)$8.6B
Repligen (RGEN)$8.3B
Ascendis Pharma (ASND)$7.7B